| [1] |
Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990—2020: a systematic review and meta-analysis[J]. The Lancet Global Health, 2017, 5(12): e1221-e1234.
|
| [2] |
Sharafeldin N, Kawaguchi A, Sundaram A, et al. Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults[J]. The British Journal of Ophthalmology, 2018, 102(11): 1485-1491.
|
| [3] |
黄育北，高鹰，戴弘季，等. 中国城市女性乳腺癌筛查卫生经济学评价[J]. 中国肿瘤临床，2019，46(16): 851-856.
|
| [4] |
John D, Parikh R. Cost-effectiveness and cost utility of community screening for glaucoma in urban India[J]. Public Health, 2017, 148: 37-48.
|
| [5] |
Müller A, Vu HT, Ferraro JG, et al. Rapid and cost-effective method to assess vision disorders in a population[J]. Clin Exp Ophthalmol, 2006, 34(6): 521-525.
|
| [6] |
柳鸿鹏，吴欣娟．国外卫生经济学评价的研究进展[J]．中华现代护理杂志，2020，26(24): 3394-3397.
|
| [7] |
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine[J]. JAMA, 2016, 316(10): 1093-1103.
|
| [8] |
Shao H, Zhai S, Zou D, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus[J]. Curr Med Res Opin, 2017, 33(2): 359-369.
|
| [9] |
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy[J]. Lancet, 2010, 10, 376(9735): 124-136.
|
| [10] |
Dwyer MS, Melton LJ, Ballard DJ, et al. Incidence of diabetic retinopathy and blindness: a population based study in Rochester Minnesota[J]. Diabetes Care, 1985, 8: 316-322.
|
| [11] |
Yau JW, Rogers SL, Kawasaki R, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care, 2012, 35(3): 556-564.
|
| [12] |
Aoki N, Dunn K, Fukui T, et al. Cost-effectiveness analysis of telemedicine to evaluate diabetic retinopathy in a prison population[J]. Diabetes Care, 2004, 27(5): 1095-1101.
|
| [13] |
Kirkizlar E, Serban N, Sisson JA, et al. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration[J]. Ophthalmology, 2013, 120: 2604-2610.
|
| [14] |
Brady CJ, Villanti AC, Gupta OP, et al. Tele-ophthalmology screening for proliferative diabetic retinopathy in urban primary care offices: an economic analysis[J]. Ophthalmic Surg Lasers Imaging Retina, 2014, 45: 556-561.
|
| [15] |
Richardson DR, Fry RL, Krasnow M. Cost-savings analysis of telemedicine use for ophthalmic screening in a rural Appalachian health clinic[J]. West Virginia Medical Journal, 2013, 109(4): 52-55.
|
| [16] |
Whited JD, Datta SK, Aiello LM, et al. A modeled economic analysis of a digital teleophthalmology system as used by three federal health care agencies for detecting proliferative diabetic retinopathy[J]. Telemed J E Health, 2005, 11: 641-651.
|
| [45] |
Magnusson G, Persson U. Screening for congenital cataracts: A cost-consequence analysis of eye examination at maternity wards in comparison to well-baby clinics[J]. Acta Paediatrica, 2005, 94(8): 1089-1095.
|
| [46] |
Chew EY, Schachat AP. Should we add screening of age-related macular degeneration to current screening programs for diabetic retinopathy？[J]. Ophthalmology, 2015, 122(11): 2155-2156.
|
| [47] |
Dimock J, Robman LD, McCarty CA, et al. Cost- effectiveness of digital cataract assessment[J]. Aust NZ Ophthalmol, 1999, 27: 208-210.
|
| [48] |
van Leeuwen R, Chakravarthy U, Vingerling JR, et al. Grading of age-related maculopathy for epidemiological studies: is digital imaging as good as 35-mm film? [J]．Ophthalmology, 2003, 110: 1540-1544.
|
| [49] |
Gangwani R, Lai WW, Sum R, et al. The incidental findings of age-related macular degeneration during diabetic retinopathy screening[J]. Graefes Arch Clin Exp Ophthalmol, 2014, 252: 723-729.
|
| [50] |
Hu CC, Ho JD, Lin HC, et al. Association between open-angle glaucoma and neovascular age-related macular degeneration: a case-control study[J]. Eye (London, England), 2017, 31(6): 872-877.
|
| [51] |
Gangwani RA, McGhee SM, Lai JS, et al. Detection of glaucoma and its association with diabetic retinopathy in a diabetic retinopathy screening program[J]. Glaucoma, 2016, 25(1): 101-105.
|
| [17] |
Li Z, Wu C, Olayiwola JN, et al. Telemedicine-based digital retinal imaging vs standard ophthalmologic evaluation for the assessment of diabetic retinopathy[J]. Conn Med, 2012, 76: 85-90.
|
| [18] |
Phan AD, Koczman JJ, Yung CW, et al. Cost analysis of teleretinal screening for diabetic retinopathy in a county hospital population[J]. Diabetes Care, 2014, 37: e252-e253.
|
| [19] |
Brown-Connolly NE, Concha JB, English J. Mobile health is worth it! Economic benefit and impact on health of a population-based mobile screening program in new Mexico[J]. Telemed J E Health, 2014, 20: 18-23.
|
| [20] |
Gomez-Ulla F, Alonso F, Aibar B, et al. A comparative cost analysis of digital fundus imaging and direct fundus examination for assessment of diabetic retinopathy[J]. Telemed J E Health, 2008, 14: 912-918.
|
| [21] |
Romero-Aroca P, de la Riva-Fernandez S, Valls-Mateu A, et al. Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up[J]. BMC Ophthalmology, 2016, 16: 136.
|
| [22] |
Bjørvig S, Johansen MA, Fossen K. An economic analysis of screening for diabetic retinopathy[J]. Telemed Telecare, 2002, 8: 32-35.
|
| [23] |
Ben AJ, Neyeloff JL, de Souza CF, et al. Cost-utility analysis of opportunistic and systematic diabetic retinopathy screening strategies from the perspective of the brazilian public healthcare system[J]. Appl Health Econ Health Policy, 2020, 18(1): 57-68.
|
| [24] |
Wu B, Li J, Wu H. Strategies to screen for diabetic retinopathy in chinese patients with newly diagnosed type 2 diabetes: a cost-effectiveness analysis[J]. Medicine (Baltimore), 2015, 94(45): e1989.
|
| [25] |
Tung TH, Shih HC, Chen SJ, et al. Economic evaluation of screening for diabetic retinopathy among Chinese type 2 diabetics: a community-based study in Kinmen, Taiwan[J]. Epidemiology, 2008, 18(5): 225-233.
|
| [26] |
Rachapelle S, Legood R, Alavi Y, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in India[J]. Ophthalmology, 2013, 120(3): 566-573.
|
| [27] |
Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus[J]. JAMA, 2000, 283(7): 889-896.
|
| [28] |
Rein DB, Wittenborn JS, Zhang X, et al. The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy[J]. Health Serv Res, 2011, 46(5): 1534-1561.
|
| [29] |
Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040[J]. Ophthalmology, 2014, 121: 2081-2090.
|
| [30] |
Moyer VA, U．S. Preventive Services Task Force. Screening for glaucoma: U．S. Preventive Services Task Force Recommendation Statement[J]. Ann Intern Med, 2013, 159(7): 484-489.
|
| [31] |
U．S. Preventive Services Task Force. Screening for glaucoma: recommendation statement[J]. Ann Fam Med, 2005, 3(2): 171-172.
|
| [32] |
Rein DB, Wittenborn JS, Lee PP, et al. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States[J]. Ophthalmology, 2009, 116: 823-832.
|
| [33] |
Burr JM, Mowatt G, Hernandez R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation[J]. Health Technol Assess, 2007, 11: 110-190.
|
| [34] |
Harasymowycz P, Fansi KA, Papamatheakis D. Screening for primary open-angle glaucoma in the developed world: are we there yet? [J]．Can Ophthalmol, 2005, 40(4): 477-86.
|
| [35] |
John D, Parikh R. Cost-effectiveness of community screening for glaucoma in rural India: a decision analytical model[J]. Public Health, 2018, 155: 142-151.
|
| [36] |
Tang JJ, Liang YB, O′Neill C, et al. Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model[J]. The Lancet Global Health, 2019, 7(7): e968-e978.
|
| [37] |
Thomas S, Hodge W, Malvankar-Mehta M. The cost-effectiveness analysis of teleglaucoma screening device[J]. PLoS One, 2015, 10(9): e0137913.
|
| [38] |
Swierk T, Jürgens C, Grossjohann R, et al. Health economical aspects of telemedical glaucoma monitoring[J]. Ophthalmologe, 2011, 108(4): 342-350.
|
| [39] |
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis[J]. Lancet Glob Health, 2014, 2: e106-e116.
|
| [40] |
Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States[J]. Arch Ophthalmol, 2006, 124(12): 1754-1760.
|
| [41] |
Hopley C, Salkeld G, Wang JJ, et al. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants[J]. Br J Ophthalmol, 2004, 88(4): 450-454.
|
| [42] |
Chan CK, Gangwani RA, McGhee SM, et al. Cost-effectiveness of screening for intermediate age-related macular degeneration during diabetic retinopathy screening[J]. Ophthalmology.2015, 122(11): 2278-2285.
|
| [43] |
Ra H, Song LD, Choi JA, et al. The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea[J]. PloS one, 2018, 13(10): e0206690.
|
| [44] |
Tamura H, Goto R, Akune Y, et al. The clinical effectiveness and cost-effectiveness of screening for age-related macular degeneration in Japan: A Markov Modeling Study[J]. PloS One, 2015, 10(7): e0133628.
|